Oral Paper Presentation
Annual Scientific Meeting
Noa Krugliak Cleveland, MD (she/her/hers)
University of Chicago Medicine, Inflammatory Bowel Disease Center
Chicago, IL
IUS (n = 11) | Non-IUS Controls (n = 19) | |
Age in years, mean (st. dev) | 44.6 (12.5) | 31.9 (10.6) |
Disease duration in years, mean (st. dev) | 14 (10.1) | 11.2 (8.7) |
Gender, % (n) | ||
Male | 55.6 (5) | 72.7 (8) |
Female | 44.4 (4) | 27.3 (3) |
IBD diagnosis, % (n) | ||
Crohn's | 44.4 (4) | 54.5 (6) |
UC | 55.6 (5) | 45.5 (5) |
Disease classification, % (n) | ||
E1 | 0.0 (0) | 0.0 (0) |
E2 | 25.0 (1) | 33.3 (1) |
E3 | 76.0 (3) | 66.7 (2) |
L1 | 0.0 (0) | 0.0 (0) |
L2 | 0.0 (0) | 16.7 (1) |
L3 | 100.0 (5) | 83.3 (5) |
L4 | 0.0 (0) | 0.0 (0) |
B1 | 40.0 (2) | 50.0 (3) |
B2 | 40.0 (2) | 0.0 (0) |
B3 | 40.0 (2) | 50.0 (3) |
Perianal disease | 20.0 (1) | 16.7 (1) |
SCCAI, mean (st. dev) | 1.8 (3.3) | 3.9 (3.5) |
HBI, mean (st. dev) | 3.5 (0.5) | 8.5 (2.4) |
Positive clinical index, % (n) | 36.4 (4) | 73.7 (14) |
Positive FCP, % (n) | 36.4 (4) | 68.4 (13) |
Positive IUS, % (n) | 100.1 (11) | |
Active disease, % (n) | 100.0 (11) | 100.0 (19) |